Switch theme
Sign up to access all valuation multiples
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
1984
66
LTM Revenue $19.8M
LTM EBITDA -$3.9M
$85.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
icad has a last 12-month revenue (LTM) of $19.8M and a last 12-month EBITDA of -$3.9M.
In the most recent fiscal year, icad achieved revenue of $19.6M and an EBITDA of -$4.9M.
icad expects next 12-month revenue of XXX and NTM EBITDA of XXX
See icad valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $19.8M | XXX | $19.6M | XXX | XXX | XXX |
| Gross Profit | $17.3M | XXX | $16.6M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | -$3.9M | XXX | -$4.9M | XXX | XXX | XXX |
| EBITDA Margin | -20% | XXX | -25% | XXX | XXX | XXX |
| EBIT | -$6.0M | XXX | -$6.3M | XXX | XXX | XXX |
| EBIT Margin | -30% | XXX | -32% | XXX | XXX | XXX |
| Net Profit | -$5.4M | XXX | -$5.6M | XXX | XXX | XXX |
| Net Margin | -27% | XXX | -29% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, icad's stock price is $4.
icad has current market cap of $105M, and EV of $85.0M.
See icad trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $85.0M | $105M | XXX | XXX | XXX | XXX | $-0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, icad has market cap of $105M and EV of $85.0M.
icad's trades at 4.3x EV/Revenue multiple, and -17.4x EV/EBITDA.
Equity research analysts estimate icad's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
icad has a P/E ratio of -19.4x.
See valuation multiples for icad and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $105M | XXX | $105M | XXX | XXX | XXX |
| EV (current) | $85.0M | XXX | $85.0M | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | -21.9x | XXX | -17.4x | XXX | XXX | XXX |
| EV/EBIT | -14.3x | XXX | -13.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -19.4x | XXX | -18.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -19.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trialicad's last 12 month revenue growth is 6%
icad's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
icad's rule of 40 is -32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
icad's rule of X is -5% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for icad and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | -20% | XXX | -25% | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -32% | XXX | -19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -5% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 117% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
icad acquired XXX companies to date.
Last acquisition by icad was XXXXXXXX, XXXXX XXXXX XXXXXX . icad acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was icad founded? | icad was founded in 1984. |
| Where is icad headquartered? | icad is headquartered in United States of America. |
| How many employees does icad have? | As of today, icad has 66 employees. |
| Who is the CEO of icad? | icad's CEO is Ms. Dana Brown. |
| Is icad publicy listed? | Yes, icad is a public company listed on NAS. |
| What is the stock symbol of icad? | icad trades under ICAD ticker. |
| When did icad go public? | icad went public in 1992. |
| Who are competitors of icad? | Similar companies to icad include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of icad? | icad's current market cap is $105M |
| What is the current revenue of icad? | icad's last 12 months revenue is $19.8M. |
| What is the current revenue growth of icad? | icad revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of icad? | Current revenue multiple of icad is 4.3x. |
| Is icad profitable? | Yes, icad is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of icad? | icad's last 12 months EBITDA is -$3.9M. |
| What is icad's EBITDA margin? | icad's last 12 months EBITDA margin is -20%. |
| What is the current EV/EBITDA multiple of icad? | Current EBITDA multiple of icad is -21.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
